Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors

BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has proven its clinical utility in hematological malignancies. Optimization is still required for its application in solid tumors. Here, the lack of cancer-specific structures along with tumor heterogeneity represent a critical barrier to sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Stock, Sophia, Benmebarek, Mohamed-Reda, Kluever, Anna-Kristina, Darowski, Diana, Jost, Christian, Stubenrauch, Kay-Gunnar, Benz, Joerg, Freimoser-Grundschober, Anne, Moessner, Ekkehard, Umana, Pablo, Subklewe, Marion, Endres, Stefan, Klein, Christian, Kobold, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341194/
https://www.ncbi.nlm.nih.gov/pubmed/35902133
http://dx.doi.org/10.1136/jitc-2022-005054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341194/
https://www.ncbi.nlm.nih.gov/pubmed/35902133
http://dx.doi.org/10.1136/jitc-2022-005054

Ejemplares similares